Russian pharmaceutical specialists developed an anti-COVID drug of new generation
The new drug Skyvira developed by Promomed Group using a unique technology received marketing authorization certificate on April 21, 2022.
Doctors say that the biggest misconception today is to believe that the coronavirus is in the past, and its new forms do not threaten people's lives.
WHO reports that as of April 20 the daily number of new reported COVID cases in the world amounted to 505 thousand; 6200 people died.
The consensus opinion of doctors is that despite some quiet period in the incidence of COVID-19 and apparent recession of pandemic in our country, SARS-Cov-2 will remain with us forever in one form or another and that new effective drugs should be developed to combat it.
«Despite some calm period in the incidence of COVID-19, and the apparent retreat of the pandemic in our country, the medical community agrees that SARS-Cov-2 in one form or another will remain with us forever. The most common strain, stealth-omicron, has practically equaled in symptoms with the usual ARVI; however, the severity of complications and post-COVID syndrome is now the highest. Future pandemics may become even more dangerous, experts already predict «deltacron» and other modifications of the virus. This makes it necessary to have a wide range of medicines for etiotropic therapy to choose from,» Kira Zaslavskaya, Director for New Products at Promomed Group, made her comment for «Novye Izvestia».
Skyvira is believed to be such a drug. It is used for outpatient treatment and attacks completely different targets specific for coronavirus. Pharmaceutical specialists draw attention to the fact that its efficacy does not depend on the coronavirus strain, both past and potential.
«Clinical studies demonstrated a pronounced antiviral effect of the new drug for COVID-19, reducing the risk of disease progression to more severe forms and accelerating recovery. The targeted mechanism of action on the viral protease determines the success of treatment, regardless of SARS-CoV-2 strain. Today, Promomed’s Skyvira can be indicated for the outpatient treatment of mild or moderate coronavirus infection in adults,» said Vladimir Chulanov, Chief Non-Staff Specialist in Infectious Diseases of the Russian Ministry of Health, Deputy Director for Research and Innovative Development of the National Medical Research Center for Phthisiopulmonology and Infectious Diseases of the Russian Ministry of Health.
Source: newizv.ru
